Cover Image
市場調查報告書

生殖器濕疣(尖頭濕疣)開發中產品分析

Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 200950
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
生殖器濕疣(尖頭濕疣)開發中產品分析 Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2016
出版日期: 2016年04月30日 內容資訊: 英文 70 Pages
簡介

生殖器濕疣(尖頭濕疣)是一般最常見的性行為感染疾病之一。積極從事性活動的人半數以上在一生的某個時刻,會感染到引起生殖器濕疣的病毒。如名字所示,生殖器濕疣對性器官潮濕的組織起作用。生殖器濕疣的外表,為小型肉色疙瘩的形式(或菜花狀外形)。大多數場合,疙瘩非常小,肉眼無法辨識。

本報告提供全球各國的生殖器濕疣 (尖頭濕疣)治療用開發中產品的開發情形相關分析、開發中產品的最新趨勢,及臨床實驗各階段產品的一覽,再加上主要企業簡介、主要藥物概要(產品概要、功能機制、研究開發(R&D)的發展情形)、最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

生殖器濕疣概要

治療藥的開發

  • 生殖器濕疣的開發中產品:概要
  • 生殖器濕疣的開發中產品:比較分析

各企業開發中的生殖器濕疣治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

生殖器濕疣治療藥:開發中產品一覽(各企業)

生殖器濕疣治療藥的開發企業

  • Helix BioPharma Corp.
  • Inovio Pharmaceuticals, Inc
  • NanoViricides, Inc
  • G&E Herbal Biotechnology Co., Ltd.
  • Anaconda Pharma
  • Foamix Ltd
  • Telormedix SA
  • Genetic Immunity, Inc
  • Xiamen Amoytop Biotech Co., Ltd

生殖器濕疣:治療藥的評估

  • 單劑治療藥的情況
  • 各標的
  • 各行動機制
  • 各投藥法
  • 分子的各類型
  • 各治療分類

藥物簡介

  • 干擾素α-2b
  • SRT-100
  • AP-611074
  • TMX-202
  • INO-3112
  • HerpeCide-I
  • 干擾素α-2b
  • imiquimod
  • HupaDerm疫苗

生殖器濕疣治療藥:最新的藥物簡介

生殖器濕疣治療藥:暫停開發的產品

生殖器濕疣治療藥:停止開發的產品

生殖器濕疣相關產品開發的里程碑

  • 值得注意的最新趨勢、新聞稿(共10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Summary

Global Markets Direct's, 'Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2016', provides an overview of the Genital Warts (Condylomata Acuminata) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Genital Warts (Condylomata Acuminata), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Genital Warts (Condylomata Acuminata) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Genital Warts (Condylomata Acuminata)
  • The report reviews pipeline therapeutics for Genital Warts (Condylomata Acuminata) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Genital Warts (Condylomata Acuminata) therapeutics and enlists all their major and minor projects
  • The report assesses Genital Warts (Condylomata Acuminata) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Genital Warts (Condylomata Acuminata)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Genital Warts (Condylomata Acuminata)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Genital Warts (Condylomata Acuminata) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Genital Warts (Condylomata Acuminata) Overview 8
  • Therapeutics Development 9
  • Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview 9
  • Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies 10
  • Genital Warts (Condylomata Acuminata) - Pipeline Products Glance 11
  • Clinical Stage Products 11
  • Early Stage Products 12
  • Genital Warts (Condylomata Acuminata) - Products under Development by Companies 13
  • Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development 14
  • Agilvax, Inc. 14
  • Aviragen Therapeutics, Inc. 15
  • Biogenomics Limited 16
  • BioMAS Ltd. 17
  • Foamix Pharmaceuticals Ltd. 18
  • G&E Herbal Biotechnology Co., Ltd. 19
  • Helix BioPharma Corp. 20
  • Laboratories Ojer Pharma S.L. 21
  • LEO Pharma A/S 22
  • Novan, Inc. 23
  • Novartis AG 24
  • Tamir Biotechnology, Inc. 25
  • Zydus Cadila Healthcare Limited 26
  • Genital Warts (Condylomata Acuminata) - Therapeutics Assessment 27
  • Assessment by Monotherapy Products 27
  • Assessment by Combination Products 28
  • Assessment by Target 29
  • Assessment by Mechanism of Action 31
  • Assessment by Route of Administration 33
  • Assessment by Molecule Type 35
  • Drug Profiles 37
  • (cervical cancer + genital warts) vaccine - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • AS-101 - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • AX-03 - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • BTA-074 - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile 44
  • Product Description 44
  • Mechanism of Action 44
  • R&D Progress 44
  • imiquimod - Drug Profile 45
  • Product Description 45
  • Mechanism of Action 45
  • R&D Progress 45
  • imiquimod SR - Drug Profile 46
  • Product Description 46
  • Mechanism of Action 46
  • R&D Progress 46
  • ingenol mebutate - Drug Profile 47
  • Product Description 47
  • Mechanism of Action 47
  • R&D Progress 47
  • interferon alfa-2b - Drug Profile 49
  • Product Description 49
  • Mechanism of Action 49
  • R&D Progress 49
  • interferon alpha-2b (recombinant) - Drug Profile 50
  • Product Description 50
  • Mechanism of Action 50
  • R&D Progress 50
  • LFX-453 - Drug Profile 52
  • Product Description 52
  • Mechanism of Action 52
  • R&D Progress 52
  • PP-210 - Drug Profile 53
  • Product Description 53
  • Mechanism of Action 53
  • R&D Progress 53
  • ranpirnase - Drug Profile 54
  • Product Description 54
  • Mechanism of Action 54
  • R&D Progress 54
  • SB-206 - Drug Profile 57
  • Product Description 57
  • Mechanism of Action 57
  • R&D Progress 57
  • SRT-100 - Drug Profile 58
  • Product Description 58
  • Mechanism of Action 58
  • R&D Progress 58
  • Genital Warts (Condylomata Acuminata) - Recent Pipeline Updates 60
  • Genital Warts (Condylomata Acuminata) - Dormant Projects 64
  • Genital Warts (Condylomata Acuminata) - Discontinued Products 65
  • Genital Warts (Condylomata Acuminata) - Product Development Milestones 66
  • Featured News & Press Releases 66
  • Dec 22, 2011: Helix BioPharma Files Clinical Trial Applications For Phase III Efficacy Trial Of Topical Interferon Alpha-2b In Patients With Low-Grade Cervical Lesions 66
  • Jun 08, 2010: Helix BioPharma Corp Announces Phase II Clinical Trial Results of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 67
  • Mar 22, 2010: Helix BioPharma Corp Achieves Last-Patient-Out In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients With Ano-Genital Warts 67
  • Sep 22, 2008: Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 68
  • Appendix 69
  • Methodology 69
  • Coverage 69
  • Secondary Research 69
  • Primary Research 69
  • Expert Panel Validation 69
  • Contact Us 69
  • Disclaimer 70

List of Tables

  • Number of Products under Development for Genital Warts (Condylomata Acuminata), H1 2016 9
  • Number of Products under Development by Companies, H1 2016 10
  • Comparative Analysis by Clinical Stage Development, H1 2016 11
  • Comparative Analysis by Early Stage Development, H1 2016 12
  • Products under Development by Companies, H1 2016 13
  • Genital Warts (Condylomata Acuminata) - Pipeline by Agilvax, Inc., H1 2016 14
  • Genital Warts (Condylomata Acuminata) - Pipeline by Aviragen Therapeutics, Inc., H1 2016 15
  • Genital Warts (Condylomata Acuminata) - Pipeline by Biogenomics Limited, H1 2016 16
  • Genital Warts (Condylomata Acuminata) - Pipeline by BioMAS Ltd., H1 2016 17
  • Genital Warts (Condylomata Acuminata) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 18
  • Genital Warts (Condylomata Acuminata) - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2016 19
  • Genital Warts (Condylomata Acuminata) - Pipeline by Helix BioPharma Corp., H1 2016 20
  • Genital Warts (Condylomata Acuminata) - Pipeline by Laboratories Ojer Pharma S.L., H1 2016 21
  • Genital Warts (Condylomata Acuminata) - Pipeline by LEO Pharma A/S, H1 2016 22
  • Genital Warts (Condylomata Acuminata) - Pipeline by Novan, Inc., H1 2016 23
  • Genital Warts (Condylomata Acuminata) - Pipeline by Novartis AG, H1 2016 24
  • Genital Warts (Condylomata Acuminata) - Pipeline by Tamir Biotechnology, Inc., H1 2016 25
  • Genital Warts (Condylomata Acuminata) - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 26
  • Assessment by Monotherapy Products, H1 2016 27
  • Assessment by Combination Products, H1 2016 28
  • Number of Products by Stage and Target, H1 2016 30
  • Number of Products by Stage and Mechanism of Action, H1 2016 32
  • Number of Products by Stage and Route of Administration, H1 2016 34
  • Number of Products by Stage and Molecule Type, H1 2016 36
  • Genital Warts (Condylomata Acuminata) Therapeutics - Recent Pipeline Updates, H1 2016 60
  • Genital Warts (Condylomata Acuminata) - Dormant Projects, H1 2016 64
  • Genital Warts (Condylomata Acuminata) - Discontinued Products, H1 2016 65

List of Figures

  • Number of Products under Development for Genital Warts (Condylomata Acuminata), H1 2016 9
  • Number of Products under Development by Companies, H1 2016 10
  • Comparative Analysis by Clinical Stage Development, H1 2016 11
  • Comparative Analysis by Early Stage Products, H1 2016 12
  • Assessment by Monotherapy Products, H1 2016 27
  • Number of Products by Top 10 Targets, H1 2016 29
  • Number of Products by Stage and Top 10 Targets, H1 2016 29
  • Number of Products by Top 10 Mechanism of Actions, H1 2016 31
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 31
  • Number of Products by Routes of Administration, H1 2016 33
  • Number of Products by Stage and Routes of Administration, H1 2016 33
  • Number of Products by Molecule Types, H1 2016 35
  • Number of Products by Stage and Molecule Types, H1 2016 35
Back to Top